PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Purchased by Voloridge Investment Management LLC

Voloridge Investment Management LLC raised its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 60.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 454,374 shares of the company's stock after buying an additional 171,029 shares during the quarter. Voloridge Investment Management LLC owned about 0.87% of PROCEPT BioRobotics worth $36,586,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Signaturefd LLC grew its position in shares of PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after buying an additional 145 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in PROCEPT BioRobotics by 1.1% in the fourth quarter. Ensign Peak Advisors Inc now owns 14,165 shares of the company's stock valued at $1,141,000 after acquiring an additional 150 shares during the period. Naviter Wealth LLC boosted its stake in PROCEPT BioRobotics by 6.0% in the fourth quarter. Naviter Wealth LLC now owns 3,089 shares of the company's stock valued at $249,000 after acquiring an additional 176 shares during the period. Amundi boosted its stake in PROCEPT BioRobotics by 0.9% in the fourth quarter. Amundi now owns 20,143 shares of the company's stock valued at $1,742,000 after acquiring an additional 183 shares during the period. Finally, Arizona State Retirement System lifted its holdings in shares of PROCEPT BioRobotics by 1.5% in the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock worth $1,150,000 after purchasing an additional 218 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $56.64 on Thursday. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of -29.05 and a beta of 1.10. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. PROCEPT BioRobotics Co. has a one year low of $47.04 and a one year high of $103.81. The stock's fifty day moving average is $55.30 and its 200-day moving average is $71.35.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The firm had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. PROCEPT BioRobotics's revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.51) EPS. Equities analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Truist Financial cut their price target on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Morgan Stanley lowered their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Bank of America lowered their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Friday, April 25th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and a consensus target price of $90.00.

Insider Buying and Selling

In related news, CFO Kevin Waters sold 733 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock valued at $368,322 over the last quarter. Corporate insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.